19 Mar 2024 , 10:35 AM
From February 20 to 23, 2024, the US FDA performed a Pre-Approval Inspection (PAI) at Piramal Pharma Limited’s Lexington, USA, plant in order to examine one of the products that is anticipated to be produced there.
A Form-483 with two observations was issued following the examination. The site’s business continuity or compliance with compliance standards are not at risk as a result of the observations. The Company is getting ready to submit to the US FDA within the allotted timeframe a comprehensive response to the aforementioned observations.
The Company is still dedicated to upholding the highest compliance standards, and it will collaborate closely with the agency to thoroughly address each and every observation.
Piramal Pharma Limited’s shares traded at ₹135.50 down 0.60% from previous close of ₹136.30.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
